Continuum Advisory’s Acadia Pharmaceuticals ACAD Stock Holding History

Continuum Advisory’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-51	Closed	-$936	–	1658
2024 Q4	$936	Buy	+51	New	+$823	﹤0.01%	1628

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

FAM

Fred Alger Management New York $30B AUM 76.99% 1-Year Est. Return

Continuum Advisory's ACAD Position: Q1 2025 in Review

Continuum Advisory sold out of Acadia Pharmaceuticals (ACAD) in Q1 2025, closing a stake of 51 shares — an estimated $936 sold.

Continuum Advisory first reported a position in ACAD in Q4 2024 and held it in 1 quarter. The position peaked at $936 in Q4 2024. 320 funds tracked by Wall St. Rank hold ACAD as of Q1 2025.

Continuum Advisory reported no remaining Acadia Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
Continuum Advisory sold 51 Acadia Pharmaceuticals shares in Q1 2025, an estimated $936.
Continuum Advisory first reported a position in Acadia Pharmaceuticals in Q4 2024 and held it in 1 quarter.
Continuum Advisory's Acadia Pharmaceuticals position peaked at $936 in Q4 2024.
320 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q1 2025.

Based on Continuum Advisory's 13F filing for Q1 2025, filed 23 Apr 2025.